Guangdong Taiankang Pharmaceutical Co., Ltd. announces its wholly-owned subsidiary, Shandong Huabokai Sheng Biotechnology Co., Ltd., has had its product, Baricitinib Tablets, selected in the 12th batch of national centralized drug procurement. This is expected to increase sales volume and market share, positively impacting future operating performance. The company will closely monitor subsequent developments.
Summary generated by AI · Always verify with source document
Guangdong Taiankang Pharmaceutical Co., Ltd.
Announcement on Wholly-Owned Subsidiary's Product Selected in National Centralized Drug Procurement
The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed in this announcement, and that there are no false records, misleading statements, or significant omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.